- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05575037
아스피린 악화 호흡기 질환에서 IL4RA 억제의 이점 메커니즘 (MARINER)
아스피린 악화 호흡기 질환에서 IL4RA 억제의 이점 메커니즘: MARINER
The overall aim of the study is to determine the clinical efficacy and mechanisms of action of anti-IL-4a (dupilumab) as treatment for patients with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) and Aspirin-Exacerbated Respiratory Disease (AERD).
연구 개요
상세 설명
The protocol involves an 8-week study of dupilumab in patients with CRSwNP and/or AERD. Participants will have 4 total doses of dupilumab administered, with each dose administered every 2 weeks. There will be full clinical assessments and biospecimen collections at Baseline (Visit 1), Week 2 (Visit 2), and Week 8 (Visit 3).
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02115
- Brigham and Women's Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Key Inclusion Criteria:
-
History of AERD, defined as meeting the diagnostic triad with:
- History of physician-diagnosed asthma and
- History of physician-diagnosed nasal polyposis and
- History of pathognomonic reactions to aspirin or other nonselective COX inhibitors.
-
Visible nasal polyps bilaterally on otoscope physical exam at the time of screening.
-
Evidence of sense of smell impairment, with a University of Pennsylvania Smell Identification Test (UPSIT) score of <34.
-
Stable asthma (no glucocorticoid burst for at least 4 weeks prior to Visit 1, and no hospitalizations or ER visits for asthma for at least the prior 3 months).
-
Consistent (daily) use of an intranasal steroid for at least 4 weeks prior to Screening.
-
No current smoking (not more than one instance of smoking in the last 3 months).
-
For females: Practicing FDA-approved methods of birth control for the duration of the study. Female participants of childbearing potential must have a negative pregnancy test upon study entry.
Key Exclusion Criteria:
- Use of investigational drugs within 12 weeks of Screening.
- Use of any biologic agent within 4 months prior to Screening.
- Use of systemic (enteral or injected) glucocorticoids within 4 weeks prior to Screening.
- History of any sinonasal surgery within 4 months prior to Screening
- Current use of zileuton
- Current use of high-dose aspirin therapy (no more than 325 mg aspirin per day will be allowed)
- Pregnant, nursing, or planning to become pregnant
Note: Other inclusion and exclusion criteria apply.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Dupilumab
Subjects will receive dupilumab (300mg every-other-week for 8 weeks). |
8-week trial of dupilumab (an anti-IL-4a) in patients with AERD.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Nasal Fluid Levels of LTE4
기간: At Week 8 (Visit 3)
|
The nasal fluid levels of LTE4 will be measured at week 8 and will serve as a surrogate biomarker of respiratory mast cell activation or burden. |
At Week 8 (Visit 3)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Nasal Fluid Levels of Albumin
기간: At Week 8 (Visit 3)
|
The nasal fluid levels of albumin will be measured at week 8 and serve as a surrogate biomarker of nasal epithelial cell integrity. |
At Week 8 (Visit 3)
|
|
Sense of Smell - University of Pennsylvania Smell Identification Test (UPSIT)
기간: At Week 8 (Visit 3)
|
Patients' sense of smell will be assessed at week 8 using the UPSIT. The UPSIT scale goes from 0 to 40, with 0 being worse (no scents identified) and 40 being best (all scents identified) |
At Week 8 (Visit 3)
|
|
Rhinoscopic Total Polyp Score (TPS)
기간: At Week 8 (Visit 3)
|
The extent of patients' nasal polyps will be assessed at week 8 using a TPS. The TPS scale goes from 0 (no polyps) to 8 (large polyps bilaterally), with 0 being best and 8 being worst. |
At Week 8 (Visit 3)
|
|
Peak Nasal Inspiratory Flow (PNIF)
기간: At Week 8 (Visit 3)
|
Patients' nasal congestion will be assessed at week 8 by a PNIF. PNIF goes from 0 mL (no airflow) to 500 mL of airflow, with 0 being worst. |
At Week 8 (Visit 3)
|
|
Quality of Life - 22-Item Sino-Nasal Outcome Test (SNOT-22)
기간: At Week 8 (Visit 3)
|
Quality of life will be assessed at week 8 with a SNOT-22. For the SNOT-22, the scores range from 0 (no symptoms, excellent disease control) to 110 (maximum sinus symptoms, poor disease control). |
At Week 8 (Visit 3)
|
|
Lung Function - Forced Expiratory Volume 1 (FEV1)
기간: At Week 8 (Visit 3)
|
Patients' lung function will be assessed at week 8 with an FEV1. |
At Week 8 (Visit 3)
|
|
Asthma Control - Asthma Control Questionnaire-6 (ACQ-6)
기간: At Week 8 (Visit 3)
|
Asthma control will be measured at week 8 with an ACQ-6. For the ACQ-6, scores ranging from 0 (well-controlled) to 6 (extremely poorly-controlled). A lower score indicates better asthma control. |
At Week 8 (Visit 3)
|
|
Number of Treatment-related Adverse Events (AEs) and Serious Adverse Events (SAEs) Leading to Study Drug Discontinuation
기간: At Week 8 (Visit 3)
|
Safety will be measured by the number of treatment-related AEs and SAEs leading to dupilumab discontinuation. |
At Week 8 (Visit 3)
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in Sense of Smell - University of Pennsylvania Smell Identification Test (UPSIT)
기간: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in UPSIT. The UPSIT scale goes from 0 to 40, with 0 being worse (no scents identified) and 40 being best (all scents identified) |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in Rhinoscopic Total Polyp Score (TPS)
기간: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in TPS. The TPS scale goes from 0 (no polyps) to 8 (large polyps bilaterally), with 0 being best and 8 being worst. |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in Peak Nasal Inspiratory Flow (PNIF)
기간: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in PNIF. PNIF goes from 0 mL (no airflow) to 500 mL of airflow, with 0 being worst. |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in 22-Item Sino-Nasal Outcome Test (SNOT-22)
기간: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in SNOT-22. For the SNOT-22, the scores range from 0 (no symptoms, excellent disease control) to 110 (maximum sinus symptoms, poor disease control). |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in Lung Function - Forced Expiratory Volume 1 (FEV1)
기간: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in FEV1. |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in Asthma Control - Asthma Control Questionnaire-6 (ACQ-6)
기간: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in ACQ-6. For the ACQ-6, scores ranging from 0 (well-controlled) to 6 (extremely poorly-controlled). A lower score indicates better asthma control. |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in Nasal Fluid Levels of Eicosanoids
기간: weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid eicosanoid levels. |
weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in Nasal Fluid Levels of Albumin
기간: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid albumin levels. |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in Urinary Levels of Eicosanoids
기간: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in urinary eicosanoid levels. |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in Serum Tryptase
기간: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in serum tryptase levels. |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in IgE Levels
기간: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid and plasma levels of IgE. |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in Eosinophilic Cationic Protein (ECP)
기간: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid levels of ECP. |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Tanya M Laidlaw, MD, Brigham and Women's Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 2022P002407
- U19AI095219 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .